Dova Pharmaceuticals (Dova Pharmaceuticals) EV-to-EBIT : -11.29 (As of Apr. 26, 2024)

Dova Pharmaceuticals EV-to-EBIT Chart

Dova Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EV-to-EBIT	Get a 7-Day Free Trial									-8.09	-1.84	-2.48	-5.01	-10.76

Competitive Comparison of Dova Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Dova Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dova Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dova Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dova Pharmaceuticals's EV-to-EBIT falls into.

Dova Pharmaceuticals EV-to-EBIT Calculation

Dova Pharmaceuticals's EV-to-EBIT for today is calculated as:

Dova Pharmaceuticals's current Enterprise Value is $807.60 Mil.
Dova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dova Pharmaceuticals  (NAS:DOVA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Dova Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

Dova Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2019 was $769.41 Mil.
Dova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dova Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description